Kite Enters into License Agreement with Arcellx for CART-ddBCMA in Multiple Myeloma

By Ayush Saxena

Pharma Deals Review: Vol 2022 Issue 12 (Table of Contents)

Published: 16 Dec-2022

DOI: 10.3833/pdr.v2022.i12.2753     ISSN: 1756-7874

Section: Licensing



In a bid to expand its cell therapy portfolio, Kite Pharma has entered into a licensing agreement with Arcellx in a deal worth up to US$4...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details